Sun Pharma Launches LEQSELVITM in US After Patent Settlement

Sun Pharmaceutical Industries has launched its novel oral treatment LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for adults with severe alopecia areata. The debut follows an out‑of‑court settlement and licensing agreement with Incyte Corporation, resolving all pending patent disputes and clearing the path for the drug’s US rollout.

LEQSELVITM, acquired through Sun Pharma’s $576 million purchase of Concert Pharmaceuticals, is a JAK1/JAK2 inhibitor that offers a much‑needed treatment for severe hair loss. In Phase III trials (THRIVE‑AA1/AA2), about one‑third of patients experienced at least 80 % scalp hair regrowth in 24 weeks.

Analysts project annual US sales of $400 million by fiscal year 2030, with peak potential of $900 million. Stock market analysts expect the launch and legal clearing to positively affect Sun Pharma’s US presence and investor sentiment.

Richard Ascroft, CEO of Sun Pharma North America, stated the launch represents “an effective, new treatment option” for patients and healthcare providers managing alopecia areata. With patent concerns resolved thanks to the settlement, the drug is now widely available by prescription across the US